Analyst Price Target is $5.00
▲ +358.72% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for AVROBIO in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 358.72% upside from the last price of $1.09.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in AVROBIO. This Buy consensus rating has held steady for over two years.
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.